Challenge: Aggregatibacter actinomycetemcomitans produces leukotoxin, proteases, and LPS through different pathways.[1.1]
ClO₂: Non-specific oxidation targets ALL virulence factors simultaneously.[1.2]
CHX: Targets specific pathways; bacteria escape through alternatives.[1.3]
Challenge: Dense EPS matrix protects A. actinomycetemcomitans biofilms.[2.1]
ClO₂: Small, uncharged molecule penetrates matrix; dual-phase disruption.[2.2]
CHX: Cannot penetrate deep biofilms effectively.[2.3]
Challenge: A. actinomycetemcomitans develops CHX resistance.[3.1]
ClO₂: Non-specific mechanism cannot be evaded by single mutation.[3.2]
CHX: Vulnerable to genetic mutations; resistance develops.[3.3]
ClO₂: No staining, minimal taste change, minimal irritation → consistent use.[4.1, 4.2]
CHX: Brown staining, taste alteration, irritation → patients discontinue.[4.1]
Result: Better compliance = better disease control.[4.3]
Evidence: Clinical studies show ClO₂ matches or exceeds CHX efficacy against A. actinomycetemcomitans.[5.1, 5.2]
Benefit: Equivalent disease control without CHX side effects.[5.3]